Results 1 to 10 of about 58,384 (313)

Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study [PDF]

open access: goldBMC Gastroenterology, 2022
Introduction Patients with ulcerative colitis (UC) are known to have a significantly poor quality of life due to bowel frequency (night) and urgent defecation.
Ryosuke Miyazaki   +8 more
doaj   +2 more sources

Long-Term Oral Budesonide Use in Inflammatory Bowel Disease: Effects on Bone Mineral Density and Late-Onset Adverse Events [PDF]

open access: yesDiagnostics
Background/Objectives: Budesonide is a corticosteroid with low systemic bioavailability, commonly used for localized treatment in inflammatory bowel disease (IBD).
Tugce Eskazan   +8 more
doaj   +2 more sources

Is It Really Feasible to Use Budesonide–Formoterol as Needed for Mild Persistent Asthma? A Systematic Review and Meta-Analysis

open access: yesFrontiers in Pharmacology, 2021
Background: Previous studies suggest that inhaled budesonide-formoterol used as needed could effectively reduce the severe exacerbation of mild persistent asthma.
Xiang Tong   +4 more
doaj   +1 more source

Budesonide

open access: yesReactions Weekly, 2006
europepmc   +2 more sources

Surfactant-Assisted Distal Pulmonary Distribution of Budesonide Revealed by Mass Spectrometry Imaging

open access: yesPharmaceutics, 2021
Direct lung administration of budesonide in combination with surfactant reduces the incidence of bronchopulmonary dysplasia. Although the therapy is currently undergoing clinical development, the lung distribution of budesonide throughout the premature ...
Riccardo Zecchi   +12 more
doaj   +1 more source

Asthma control with ICS-formoterol reliever versus maintenance ICS and SABA reliever therapy: a post hoc analysis of two randomised controlled trials

open access: yesBMJ Open Respiratory Research, 2022
Background In randomised controlled trials, as-needed inhaled corticosteroid (ICS)-formoterol reliever therapy reduces severe exacerbation risk compared with maintenance ICS plus short-acting beta2-agonist (SABA) reliever in adolescent and adult asthma ...
  +21 more
doaj   +1 more source

New Strategies for Improving Budesonide Skin Retention

open access: yesPharmaceutics, 2021
The aim of this work was to evaluate the ex vivo effect of the combination of two strategies, complexation with cyclodextrin, and poloxamer hydrogels, for improving water solubility in the dermal absorption of budesonide.
Cristina Padula   +3 more
doaj   +1 more source

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis

open access: yesTherapeutic Advances in Gastroenterology, 2023
Background: Low bioavailability steroids, including beclomethasone dipropionate (BDP) and budesonide MMX, have been developed to ensure colonic targeting and low systemic activity than systematic corticosteroids in treating patients with ulcerative ...
Brigida Barberio   +8 more
doaj   +1 more source

Budesonide Analogues Preserve Stem Cell Pluripotency and Delay 3D Gastruloid Development

open access: yesPharmaceutics, 2023
Small molecules that can modulate or stabilize cell–cell interactions are valuable tools for investigating the impact of collective cell behavior on various biological processes such as development/morphogenesis, tissue regeneration and cancer ...
Filomena Amoroso   +12 more
doaj   +1 more source

Development and validation of analytical methods for selective determination of albuterol and budesonide in Airsupra inhalation aerosol using spectrophotometry

open access: yesScientific Reports, 2023
Airsupra inhalation aerosol is a recently approved FDA medication that combines albuterol and budesonide for treating or preventing bronchoconstriction and lowering the risk of relapses in asthma patients who are 18 years of age and older. To selectively
Atiah H. Almalki   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy